Trial Search Results

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
  • Drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine


Phase 3


Inclusion Criteria:

   - Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical
   staining; myelodysplasia; or biphenotypic leukemia.

   - Age less than or equal to 21 years at time of study entry.

   - No prior therapy for this malignancy (patients with secondary AML following treatment
   of primary malignancy are eligible) except for one dose of intrathecal therapy.

   - Negative pregnancy test

   - Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile
   myelomonocytic leukemia (JMML)

Exclusion Criteria:

   - Positive pregnancy test

   - Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
LPCH New Patient Coordinator
Not Recruiting